Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes

被引:1
作者
Van Ark-Otte, J [1 ]
Samelis, G [1 ]
Rubio, G [1 ]
Saez, JBL [1 ]
Pinedo, HM [1 ]
Giaccone, G [1 ]
机构
[1] Free Univ Amsterdam Hosp, Dept Oncol, NL-1081 HV Amsterdam, Netherlands
关键词
P-glycoprotein; multidrug resistance protein; taxol; taxotere; rhizoxin;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug sensitivity was studied for the tubulin inhibitors taxol, taxotere, rhizoxin and for doxorubucin and cisplatin, in human lung and breast cancer cell lines, including drug-selected cell lines, overexpressing the membrane transporter P-glycoprotein (Pgp) or the multidrug resistance protein (MRP). All tubulin-inhibiting agents were more potent than doxorubicin and cisplatin in all cell lines. In the drug resistance-selected cell lines (doxorubicin or mitoxantrone resistant) there was cross-resistance between the tubulin inhibitors and the selecting agent; however, MRP overexpressing cells were relatively less resistant to taxanes than the Pgp overexpressing cells. Polymerization of microtubules after exposure to taxol was observed in drug sensitive cell lines, but not in resistant cell lines, even at high taxol concentrations and after long exposure times. In the Pgp overexpressing cell lines, steady accumulation of C-14-taxol was defective and could be reverted by verapamil. MRP overexpressing cells did not have a significant accumulation defect of taxol, compared to the parental cell lines, and verapamil did not have any effect. These data confirm that the Pgp overexpression is an important mechanism of resistance to taxanes and rhizoxin in human lung and breast tumor cells. However, the presence of mechanims other than transport defects may play an important role in non-Pgp expressing cells, and these may include an altered function of tubulins.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 43 条
[1]   MRP GENE OVEREXPRESSION IN A HUMAN DOXORUBICIN-RESISTANT SCLC CELL-LINE - ALTERATIONS IN CELLULAR PHARMACOKINETICS AND IN PATTERN OF CROSS-RESISTANCE [J].
BINASCHI, M ;
SUPINO, R ;
GAMBETTA, RA ;
GIACCONE, G ;
PROSPERI, E ;
CAPRANICO, G ;
CATALDO, I ;
ZUNINO, F .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (01) :84-89
[2]  
BREUNINGER LM, 1995, CANCER RES, V55, P5342
[3]  
Broxterman Henk J., 1995, Current Opinion in Oncology, V7, P532, DOI 10.1097/00001622-199511000-00011
[4]  
BROXTERMAN HJ, 1991, J CELL PHARM, V2, P239
[5]   TAXOL-REQUIRING MUTANT OF CHINESE-HAMSTER OVARY CELLS WITH IMPAIRED MITOTIC SPINDLE ASSEMBLY [J].
CABRAL, F ;
WIBLE, L ;
BRENNER, S ;
BRINKLEY, BR .
JOURNAL OF CELL BIOLOGY, 1983, 97 (01) :30-39
[6]   A MECHANISM OF CELLULAR-RESISTANCE TO DRUGS THAT INTERFERE WITH MICROTUBULE ASSEMBLY [J].
CABRAL, FR ;
BRADY, RC ;
SCHIBLER, MJ .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1986, 466 :745-756
[7]  
COLE SPC, 1994, CANCER RES, V54, P5902
[8]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[9]   DOCETAXEL [J].
CORTES, JE ;
PAZDUR, R .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2643-2655
[10]  
Dumontet C, 1996, CANCER RES, V56, P1091